Showing 5921-5930 of 8204 results for "".
- RILECSU Study: Rilzabrutinib Effective for Symptoms in Hard-to-Treat Urticariahttps://practicaldermatology.com/news/rilecsu-trial-rilzabrutinib-eases-symptoms-in-hard-to-treat-urticaria/2474350/Rilzabrutinib significantly reduced itch and hives in adults with antihistamine-refractory chronic spontaneous urticaria (CSU), according to new phase 2 trial results published in JAMA Dermatology.
- From ASLMS 2025: E. Victor Ross, MD, Talks Landscape of Fractional Laser Treatmentshttps://practicaldermatology.com/news/from-aslms-e-victor-ross-md-explores-landscape-of-fractional-laser-treatments/2474326/At the 2025 American Society for Laser Medicine and Surgery (ASLMS) Annual Meeting in Orlando, E. Victor Ross, MD, shared insights on the evolving role of fractional lasers in dermatologic practice, highlighting both their advantages and limitations. Risk, Recovery, and Pigmentatio
- From ASLMS 2025: New Laser Platforms Expand Options for Vascular Rosaceahttps://practicaldermatology.com/news/new-laser-platforms-expand-options-for-vascular-rosacea/2474325/Advanced vascular lasers are transforming the treatment of rosacea by targeting its root cause (chronic vascular dilation) rather than just managing inflammation. At the 2025 American Society for Laser Medicine and Surgery (ASLMS) Annual Meeting in Orlando, Eric Bernstein, MD, Director of
- Tattoo Removal Trends Revealed in Global Analysis of Over 200,000 Individualshttps://practicaldermatology.com/news/tattoo-removal-trends-revealed-in-global-analysis-of-over-200000-individuals/2474320/Laser tattoo removal is increasingly sought by individuals across the globe, according to new research presented at the American Society for Laser Medicine and Surgery (ASLMS) Annual Meeting in Orlando. The data were presente
- AVAVA Receives FDA Clearance for Acne Scar Treatment on All Skin Types Using Focal Point Technologyhttps://practicaldermatology.com/news/avava-receives-fda-clearance-for-acne-scar-treatment-on-all-skin-types-using-focal-point-technology/2474319/The U.S. Food and Drug Administration (FDA) has cleared AVAVA’s Focal Point Technology™ for the treatment of acne scars, marking a significant milestone in energy-based skin therapy. The technology, developed by Boston-based AVAVA, is now indicated for acne scarring in all Fitzpatrick sk
- Alemtuzumab Highly Effective in CTCL Without Papular History: Analysishttps://practicaldermatology.com/news/study-alemtuzumab-highly-effective-in-ctcl-without-papular-history/2474209/A new analysis suggests the absence of papules, plaques, and tumors (PPT) in cutaneous T-cell lymphoma (CTCL) may predict favorable clinical outcomes with low dose alemtuzumab (LDA) therapy. In a retrospective cohort study
- Survey Reveals Clinician Views on CHE's Impact on Quality of Lifehttps://practicaldermatology.com/news/Survey-Reveals-Clinician-Views-CHEs-Impact-Quality-Life/2474228/Ninety-five percent of US dermatology clinicians surveyed agreed moderate-to-severe chronic hand eczema (CHE) has a strong impact on patients’ work and home life, according to the second phase of a survey sponsored by LEO Pharma Inc., the company announced in a press release. The survey, w
- Report: 5-FU and Imiquimod Combo May Offer Enhanced Actinic Keratosis Clearancehttps://practicaldermatology.com/news/report-5-fu-and-imiquimod-combo-may-offer-enhanced-actinic-keratosis-clearance/2474234/Combining 5-fluorouracil (5-FU) and imiquimod may enhance therapeutic efficacy for actinic keratoses (AK), according to emerging data. "To date, the combination of 5-FU and imiquimod, 2 of the most used monotherapies, remain
- Pelthos Therapeutics and Channel Therapeutics to Mergehttps://practicaldermatology.com/news/pelthos-therapeutics-and-channel-therapeutics-to-merge/2474190/Ligand Pharmaceuticals has announced a definitive merger agreement that will combine its wholly owned subsidiary Pelthos Therapeutics with Channel Therapeutics Corporation, forming a publicly traded company under the name Pelthos Therapeutics Inc. The deal is suppo
- Study: Strontium May Help Alleviate Pruritus for HS Patientshttps://practicaldermatology.com/news/Study-Strontium-May-Help-Alleviate-Pruritus-HS-Patients/2474128/Strontium cream demonstrated promise as a therapeutic option for managing pruritus in hidradenitis suppurativa (HS), according to a new research article published in the Journal of Clinical and Aesthetic Dermatology. In a prospective, open-label, real-world study involving 50 part